HEPARIN SODIUM (heparin sodium) by Medica Corp is protein, antithrombin iii, to induce a conformational change, which markedly enhances the serine protease activity of antithrombin ii, thereby inhibiting the activated coagulation factors involved in the closing sequence, particularly xa and iia. First approved in 1978.
Drug data last refreshed Yesterday
Heparin Sodium is an injectable anticoagulant that works by enhancing antithrombin III activity to inhibit coagulation factors Xa and IIa, preventing thrombus formation. It is used across multiple indications including venous thromboembolism, deep vein thrombosis, acute myocardial infarction, and percutaneous coronary intervention. Heparin does not dissolve existing clots but prevents their expansion and formation.
As an established injectable with LOE approaching, the brand team is likely focused on lifecycle management and defending market share against oral anticoagulants rather than growth initiatives.
protein, antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin II, thereby inhibiting the activated coagulation factors involved in the closing sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study With Heparin Sodium in Subcutaneous Administration
Study With Heparin Sodium in Intravenous Administration
Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)
Worked on HEPARIN SODIUM at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Heparin Sodium offers exposure to mature product lifecycle management, hospital/institutional selling, and competitive defense against newer anticoagulants in a generic-heavy market. Opportunities emphasize cost-effectiveness, clinical evidence leverage, and institutional relationships rather than innovation-driven growth.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo